AVAH

EX-99.1

2 avah-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FIRST

QUARTER FINANCIAL RESULTS AND REVISED 2026 GUIDANCE

• First Quarter Revenue was $647.9 million, a 15.9% increase over the prior year period

• First Quarter Net income was $41.7 million compared to $5.2 million for the prior year period

• Adjusted EBITDA for Q1 2026 was $84.4 million, a 25.2% increase over the prior year period

• Increased Full Year 2026 Revenue guidance to between $2.56 and $2.58 billion, updated from between $2.54 and $2.56 billion

o Increased Full Year 2026 Adjusted EBITDA guidance to between $328 and $332 million, updated from between $318 and $322 million

Atlanta, Georgia (May 14, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period ended April 4, 2026.

Jeff Shaner, Chief Executive Officer, commented, “Q1 reflects the strength and resiliency of our business model with an impressive start to 2026. Our first quarter results saw revenue and adjusted EBITDA increase 15.9% and 25.2%, respectively, when compared to the prior year period, and our guidance has been revised to reflect the positive momentum we see in 2026. Our Preferred Payor and Government Affairs strategies underpin the continued growth across all of our business segments. Most importantly, our clinical teams continue to deliver on our mission, bringing high quality care to our patients in the comfort of their homes. While we finalize the regulatory approval process on the Family First Homecare transaction, our focus remains on delivering strong organic growth across Aveanna’s national footprint. Finally, thank you to our Aveanna team for your hard work, dedication, and commitment to exceptional care. You are the true heart of our company."

Three-Month Period Ended April 4, 2026 and March 29, 2025

Revenue was $647.9 million for the three-month period ended April 4, 2026, as compared to $559.2 million for the three-month period ended March 29, 2025, an increase of $88.7 million, or 15.9%. The overall increase in revenue was attributable to a $75.7 million increase in PDS segment revenue, a $9.9 million increase in HHH segment revenue, and a $3.2 million increase in MS segment revenue compared to the first three months of 2025.

Gross margin was $205.4 million, or 31.7% of revenue, for the three-month period ended April 4, 2026, as compared to $183.6 million, or 32.8% of revenue, for the three-month period ended March 29, 2025, an increase of $21.9 million, or 11.9%.

Net income was $41.7 million for the three-month period ended April 4, 2026, as compared to net income of $5.2 million for the three-month period ended March 29, 2025. Net income per diluted share was $0.19 for the three-month period ended April 4, 2026, as compared to net income per diluted share of $0.03 for the three-month period ended March 29, 2025. Adjusted net income per diluted share was $0.18 for the three-month period ended April 4, 2026, as compared to adjusted net income per diluted share of $0.10 for the three-month period ended March 29, 2025. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $84.4 million, or 13.0% of revenue, for the three-month period ended April 4, 2026, as compared to $67.4 million, or 12.0% of revenue, for the three-month period ended March 29, 2025, an increase of $17.0 million or 25.2%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

1

Liquidity, Cash Flow, and Debt

• As of April 4, 2026, we had cash of $189.3 million and incremental borrowing capacity of $110.0 million under our securitization facility. Our revolver was undrawn, with approximately $225.5 million of borrowing capacity and approximately $24.5 million of outstanding letters of credit. The pending acquisition, which is being funded with a combination of cash on hand and borrowings under our securitization facility, is expected to reduce our liquidity upon the closing of the transaction.

• 2026 net cash provided by operating activities was $4.3 million. Free cash flow was $(3.8) million for the three-month ended April 4, 2026. See “Non-GAAP Financial Measures - Free cash flow” below.

• As of April 4, 2026 we had total indebtedness of $1,483.4 million. Our interest rate exposure under our credit facilities is currently hedged with the following instruments:

o $520.0 million notional amount of interest rate swaps that convert variable rate debt to a fixed rate, and

o $880.0 million notional amount of interest rate caps that cap our exposure to SOFR at 2.96%.

Matt Buckhalter, Chief Financial Officer, commented “We are pleased with our strong start to 2026. Our team continued to execute at a high level across all three divisions. For the first quarter, we delivered reven

EX-99.1

2 avah-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

AVEANNA HEALTHCARE HOLDINGS ANNOUNCES FOURTH

QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

• Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year period

• Fourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year period

• Adjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year period

• Maintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion

o Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million

• Announced agreement to acquire Family First Homecare subsequent to the Fourth Quarter

Atlanta, Georgia (March 19, 2026) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three-month period and fiscal year ended January 3, 2026.

Jeff Shaner, Chief Executive Officer, commented, “The strength and momentum of all three operating divisions can be seen in our fourth quarter results as we complete the third year of our Strategic Transformation. Fourth quarter results are headlined by revenue and adjusted EBITDA growth of 27.4% and 54.0%, respectively, when compared to the prior year period. With the integration of Thrive Skilled Pediatric Care completed, we are well-positioned for further acquisition activity, including the recently announced Family First Homecare transaction. Our confirmed guidance underscores the strength of our core business model as we continue to provide high quality and cost-effective care to our patients in their preferred care setting – the home. These results reflect the extraordinary efforts and the determination of our entire team at Aveanna, who deliver on our mission of exceptional care every day.”

Three-Month Periods Ended January 3, 2026 (14 weeks) and December 28, 2024 (13 weeks)

Revenue was $662.5 million for the three-month period ended January 3, 2026, as compared to $519.9 million for the three-month period ended December 28, 2024, an increase of $142.6 million, or 27.4%. The overall increase in revenue was attributable to a $118.5 million increase in PDS segment revenue, a $14.9 million increase in HHH segment revenue, and a $9.2 million increase in MS segment revenue compared to the fourth quarter of 2024.

Gross margin was $213.3 million, or 32.2% of revenue, for the three-month period ended January 3, 2026, as compared to $171.7 million, or 33.0% of revenue, for the three-month period ended December 28, 2024, an increase of $41.6 million, or 24.2%.

Net income was $178.8 million for the three-month period ended January 3, 2026, as compared to net income of $29.2 million for the three-month period ended December 28, 2024. Net income per diluted share was $0.80 for the three-month period ended January 3, 2026, as compared to net income per diluted share of $0.14 for the three-month period ended December 28, 2024. Adjusted net income per diluted share was $0.17 for the three-month period ended January 3, 2026, as compared to adjusted net income per diluted share of $0.05 for the three-month period ended December 28, 2024. See "Non-GAAP Financial Measures - Adjusted net income and Adjusted net income per diluted share" below.

Adjusted EBITDA was $85.0 million, or 12.8% of revenue, for the three-month period ended January 3, 2026, as compared to $55.2 million, or 10.6% of revenue, for the three-month period ended December 28, 2024, an increase of $29.8 million or 54.0%. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.

Year Ended January 3, 2026 and December 28, 2024

1

Revenue was $2,433.2 million for the fiscal year ended January 3, 2026, as compared to $2,024.5 million for the fiscal year ended December 28, 2024, an increase of $408.7 million, or 20.2%. The overall increase in revenue was attributable to a $366.5 million increase in PDS segment revenue, a $30.8 million increase in HHH segment revenue, and a $11.4 million increase in MS segment revenue compared to the fiscal year 2024.

Gross margin was $810.5 million, or 33.3% of revenue, for the fiscal year ended January 3, 2026, as compared to $635.5 million, or 31.4% of revenue, for the fiscal year ended December 28, 2024, an increase of $174.9 million, or 27.5%.

Net income was $225.0 million for the fiscal year ended January 3, 2026, as compared to net loss of $10.9 million for the fiscal year ended December 28, 2024. Net income per diluted share was $1.05 for the fiscal year ended January 3, 2026, as compared to net loss per diluted share of $(0.06) for the fiscal year ended December 28, 2024. Adjusted net income per diluted share was $0.60 for the fiscal year ended January 3, 2026, as compared to adjusted net income per diluted share of $0.06 for the fiscal year ended December 28, 2024. See "Non-GAAP Financial Measures - Adjusted net incom

8-K

0001832332false00018323322026-01-142026-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

Aveanna Healthcare Holdings Inc. (Exact name of Registrant as Specified in Its Charter)

Delaware

001-40362

81-4717209

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

400 Interstate North Parkway SE

Atlanta, Georgia

30339

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 770 441-1580

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.01 per share

AVAH

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. On January 14, 2026, Aveanna Healthcare Holdings Inc. (the "Company", "we", "us", or "our"), issued a press release updating its full year guidance for fiscal year 2025 (year ending January 3, 2026) and announcing its full year guidance for fiscal year 2026 (year ending January 2, 2027). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02. Item 7.01 Regulation FD Disclosure. On January 14, 2026, the Company made available a financial presentation to investors. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on our website at ir.aveanna.com.

Use of our Website and Social Media to Distribute Material Company Information

We use our website as a channel of distribution for important Company information. We routinely post on our website important information, including press releases, investor presentations and financial information, which may be accessed by clicking on the “Investors” section of www.aveanna.com. We also use our website to expedite public access to time-critical information regarding our Company in advance of or in lieu of distributing a press release or a filing with the SEC disclosing the same information. Therefore, investors should look to the “Investors” section of our website for important and time-critical information. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, and this Item 7.01, including in Exhibit 99.2 attached hereto, are “furnished” and not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act, except to the extent such other filing specifically incorporates such information by reference. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

Exhibit Number

Description

99.1

Press Release Announces Updated Full Year 2025 and Initial Full Year 2026 Guidance

99.2

Aveanna Investor Presentation - January 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AVEANNA HEALTHCARE HOLDINGS INC.

Date:

January 14, 2026

By:

/s/ Matthew Buckhalter

Matthew Buckhalter Chief Financial Offi